Ascelia Pharma AB (publ) (STO: ACE)

Market Cap	256.05M
Revenue (ttm)	n/a
Net Income (ttm)	-62.30M
Shares Out	96.08M
EPS (ttm)	-1.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	513,050
Open	2.730
Previous Close	2.720
Day's Range	2.600 - 2.780
52-Week Range	1.889 - 17.980
Beta	1.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 trial for the treatment of gastric cancer. Ascelia Pharma AB (publ) was incorporated in 1999 and is based in Malmö, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACE